Andrew Cakana
- Hematology top 0.5%
- Molecular Biology top 5%
- Oncology top 5%
- Genetics top 5%
- Epidemiology
- Co-authors
- Helgi van de VeldeWilliam DeraedtJesús F. San MiguelPaul G. RichardsonOfer ShpilbergRudolf SchlagMeletios Α. DimopoulosMartin Kropff
- Topics
- Multiple Myeloma Research and Treatments (35 papers)Protein Degradation and Inhibitors (15 papers)Cancer Treatment and Pharmacology (11 papers)
- Cited by
- HematologyOncologyGenetics
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Andrew Cakana
48 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 69
- Hematology 1.5k
- Molecular Biology 1.4k
- Oncology 948
- Genetics 299
- Epidemiology 84
Countries citing papers authored by Andrew Cakana
This map shows the geographic impact of Andrew Cakana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Cakana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Cakana more than expected).
Fields of papers citing papers by Andrew Cakana
This network shows the impact of papers produced by Andrew Cakana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Cakana. The network helps show where Andrew Cakana may publish in the future.
Co-authorship network of co-authors of Andrew Cakana
This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Cakana. A scholar is included among the top collaborators of Andrew Cakana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Cakana. Andrew Cakana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 30 | |
| 3 | 3 | |
| 4 | 3 | |
| 5 | 1 | |
| 6 | 19 | |
| 7 | 150 | |
| 8 | 58 | |
| 9 | 39 | |
| 10 | 68 | |
| 11 | 87 | |
| 12 | 2 | |
| 13 | 37 | |
| 14 | 8 | |
| 15 | 100 | |
| 16 | 312 | |
| 17 | 112 | |
| 18 | 13 | |
| 19 | 199 | |
| 20 | 12 |
About Andrew Cakana
Andrew Cakana is a scholar working on Hematology, Oncology and Genetics, having authored 48 papers that have together received 1.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (35 papers), Protein Degradation and Inhibitors (15 papers) and Cancer Treatment and Pharmacology (11 papers). The work is most often cited by research in Hematology (1.5k citations), Oncology (948 citations) and Genetics (299 citations). Andrew Cakana has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Helgi van de Velde, William Deraedt, Jesús F. San Miguel, Paul G. Richardson, Ofer Shpilberg, Rudolf Schlag, Meletios Α. Dimopoulos, Martin Kropff, M. Bayssas and George Chen. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.